Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Interleukin-12 for AIDS-Related Kaposi’s Sarcoma Running head: IL-12 AND LIPOSOMAL DOXORUBICIN FOR KAPOSI’S SARCOMA

(4217 articles) Neoplasia • (5022 articles) Immunobiology • (3722 articles) Clinical Trials and Observations • Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at:

[1]  S. Steinberg,et al.  Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. , 2006, Blood.

[2]  S. Monfardini,et al.  Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. , 2005, International journal of oncology.

[3]  R. Yarchoan,et al.  Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management , 2005, Nature Clinical Practice Oncology.

[4]  R. Pfeiffer,et al.  Survival After Cancer Diagnosis in Persons With AIDS , 2005, Journal of acquired immune deficiency syndromes.

[5]  A. Tulpule,et al.  Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Diamond,et al.  Malignancy‐related causes of death in human immunodeficiency virus‐infected patients in the era of highly active antiretroviral therapy , 2005, Cancer.

[7]  A H Gandjbakhche,et al.  Quantitative Assessment of Tumor Vasculature and Response to Therapy in Kaposi's Sarcoma Using Functional Noninvasive Imaging , 2004, Technology in cancer research & treatment.

[8]  D. Podzamczer,et al.  Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma , 2004, AIDS.

[9]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[10]  S. Krown.  Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. d’Arminio Monforte,et al.  AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Sparreboom,et al.  Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses , 2003 .

[13]  S. Pittaluga,et al.  A pilot study of cidofovir in patients with kaposi sarcoma. , 2003, The Journal of infectious diseases.

[14]  A. Sparreboom,et al.  Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  A. Jemal,et al.  Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. , 2002, Journal of the National Cancer Institute.

[16]  D. Katzenstein,et al.  A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection , 2002, AIDS.

[17]  S. Chevret,et al.  Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. , 2001, The Journal of investigative dermatology.

[18]  D. Podzamczer,et al.  Response to Liposomal Doxorubicin and Clinical Outcome of HIV-1–Infected Patients with Kaposi’s Sarcoma Receiving Highly Active Antiretroviral Therapy , 2001, HIV clinical trials.

[19]  S. Steinberg,et al.  Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. , 2001, The Journal of infectious diseases.

[20]  J. Kaldor,et al.  Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy , 2001, AIDS.

[21]  J. Gutkind,et al.  The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. , 2000, Cancer research.

[22]  P. Aegerter,et al.  Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients , 2000 .

[23]  E. Tartour,et al.  Cytokines and soluble cytokine receptor induction after IL‐12 administration in cancer patients , 2000, Clinical and experimental immunology.

[24]  J. Gutkind,et al.  The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. , 2000, Cancer research.

[25]  Charles D. McDermott,et al.  Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  O. Arrieta,et al.  Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. , 1998, European journal of cancer.

[27]  E. Geras-Raaka,et al.  Human Interferon-γ–inducible Protein 10 (IP-10) Inhibits Constitutive Signaling of Kaposi's Sarcoma–associated Herpesvirus G Protein–coupled Receptor , 1998, The Journal of experimental medicine.

[28]  E. Cesarman,et al.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[29]  R. Herbst,et al.  Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models , 1998, Cancer Chemotherapy and Pharmacology.

[30]  M. Testa,et al.  AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Nakamura,et al.  Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. , 1997, Journal of immunology.

[32]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .

[33]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. , 1997, Blood.

[34]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma , 1996, Journal of virology.

[35]  D. Herndon,et al.  Interleukin‐12 protects thermally injured mice from herpes simplex virus type 1 infection , 1996, Journal of leukocyte biology.

[36]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[37]  B. Teicher,et al.  Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma , 1996, Cancer Chemotherapy and Pharmacology.

[38]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[39]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[40]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[41]  F. Goebel,et al.  Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. , 1994, Journal of acquired immune deficiency syndromes.

[42]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[43]  J. V. Von Roenn,et al.  Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. , 1993, American journal of epidemiology.

[44]  B. Gazzard,et al.  Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

[45]  J. Ritz,et al.  Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. , 1993, Blood.

[46]  S. Kaufmann,et al.  The role of T-cell subsets and cytokines in the regulation of infection. , 1991, Immunology today.

[47]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[48]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[49]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .

[50]  T. Waldmann,et al.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.